Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

Adam Pearson used his neurofibromatosis struggles to succeed in acting and advocacy, inspiring others to accept differences ...

RENO, Nev. (KOLO) - Saturday, Feb. 22 hundreds of people in Reno will take to the streets in just their undies during Cupid’s Undie Run. The event raises awareness of neurofibromatosis (NF), a genetic ...

Cupid's Undie Run sent dozens of half-naked runners through Saturday to raise awareness for a genetic disease.

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...

Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

TD Cowen analysts increased their price target for Spring Works Therapeutics (NASDAQ:SWTX) shares to $66.00 from $63.00, while maintaining a "Buy" rating on the stock. The company's shares, currently ...

The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have unresectable symptomatic plexiform neurofibromas.